Cerebrolysin—also known as FPE 1070—is a synthetic nootropic drug. Nootropic drugs are substances that enhance cognitive functions such as memory, creativity, and motivation in otherwise healthy individuals. This peptide is extremely small, allowing it to penetrate the blood-brain barrier and act directly on the neurons of the central nervous system. Cerebrolysin has been found to improve the metabolic activity of brain tissue, shield neurons from harmful substances, and stimulate the peripheral and central nervous systems. In addition to its utility as a nootropic substance, the drug has potential as part of a treatment plan addressing Alzheimer’s disease, stroke, and moderate to severe head injury.
Although growth hormone and growth hormone releasing hormones are classified as prescription drugs, there is a safe and legal way to increase your levels of hGH production. There are a range of growth hormone supplements designed to boost hGH production within normal limits. For more information, please refer to our “Natural Growth Hormone Supplements Guide”.
We organise and run biennial international scientific conferences, satellites and support local state meetings. Our meetings are designed to be in the fashion of the relaxed Gordon conference – with about 200 delegates and with a friendly and a highly participatory atmosphere. We also have a strong commitment to our early career researchers and students.
Serum IGF-1 levels remained relatively constant over the dosing period with no apparent differences between treatment groups. Fasting plasma glucose and serum insulin levels remained unchanged throughout the treatment period. Furthermore, no changes in any of the OGTT parameters were observed from day 1 to day 7 of treatment. There were no study related clinically significant findings in the safety related laboratory tests, vital signs, or ECG measurements.
The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human growth hormone, but found that this was not the case, meaning that the fact this peptide resembled hGH was meaningless. Scientists were unable to determine how this peptide was working in mice (6).

Follow the same routine as shown above for "intermediate" persons. However, as soon as possible after your weight training you should also inject 200mcg of PEG-MGF (IGF-1e) and/or 50mcg of IGF-1 LR3 preferably into a muscle (although due to the long half-life of both products, sub-q injections are also acceptable). If injecting intramuscularly, you should make sure that the muscle you are injecting into is not covered by a thick layer of fat. Usually due to the length of insulin syringe needles, injections are therefore limited to the biceps for most persons.
When the AFL Peptides scandal hit, Calzada was forced to clarify the facts about AOD9604, and put out a cleverly worded press statement aimed at potential investors, concentrating on the fact that AOD9604 had been proven safe in large scale clinical trials (neglecting to mention a lack of effectiveness) and spoke of the success of AOD9604 on stimulating bone growth, and on cartilage and muscle cell repair in in-vitro trials (2,4). The black market uses for this peptide in muscle repair and treatment of obesity were also mentioned in the release, and it is clear through media reports on this scandal that Calzada gained traction from the profile boost (8).

Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used in the management of mild to moderate pain and inflammation in conditions such as dysmenorrhoea, headache including migraine, post-operative pain, dental pain, musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile idiopathic arthritis, peri-articular disorders such as bursitis and tenosynovitis, and soft tissue disorders such as sprains and strains. It is also used to reduce fever.
A total of 97 AEs were reported by 17/17 subjects during this study. Most of them were of mild or moderate in intensity, with the exception of two SAEs, one of which (diarrhoea) was deemed “possibly related” to study treatment (54 mg AOD9604) and one (bronchial pneumonia) deemed to be “unrelated” to the study treatment (54 mg AOD9604). The most common adverse event reported was mild or moderate headache followed by events related to the digestive system, specifically diarrhea, flatulence, increased appetite and nausea. There was no observable trend between the AOD9604 groups or the placebo with respect to the incidence. The only event deemed definitely related to the treatment was taste perversion occurring 10 minutes following dose administration of the placebo.
Studies have shown that individuals fighting infection have a lower amount of circulating T α 1 and suppressed helper T cell numbers compared to healthy individuals. This is problematic, as optimal immune function is vital to recovery from infection. Supplementation with T α 1 has the potential for great therapeutic benefit for patients suffering from infection or autoimmune disease.
Monash University discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 176-191, is less than 10% of the total size of the GH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural Growth Hormone regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified Growth Hormone. Like Growth Hormone, AOD 9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (the transformation of nonfat food materials into body fat) both in laboratory testing and in animals and humans. Recent findings have shown, in addition to its fat loss properties, AOD 9604 processes many other regenerative properties associated with growth hormone. Currently trials are underway to show the application of AOD 9604 in osteoarthritis, hypercholesterolemia, bone and cartilage repair. AOD 9604 has an excellent safety profile, recently obtaining Human GRAS status in the USA.

Taking it consistently for about 3 months and my BF was consistent (say 12-13%). Then, on a not so strict diet, I just seemed to lose an inch in my waist, maybe going consistenly 12% BF or lower...not sure. No change in AAS 250test/400Deca EW) or other supps. Strength was never an issue and never pushed myself to the limit on lifting but felt I could do even more than I did.
I stopped the colostrum and my ” symptoms ” subsided, seems I have a moderately enlarged prostate which doesn’t run in my family on either side, my question is could the colostrum possibly cause the prostate to enlarge due to the igf-1 at a certain age,? due to a possible decline in testosterone, or could the benefits of colostrum outweigh the prostate issue?
Django Nathan, a medical doctor with a degree in molecular biology and genetics, takes peptides because of his busy lifestyle: "Quite a few doctors I know are using them because they have so many beneficial effects and so few side effects. We're not elite athletes – we live rushed lives that can involve 70 hour weeks so staying fit and getting good sleep is essential – and peptides aid that."
The expression of β3-AR RNA was assessed by RT by using radiolabeled primers and Southern blot analysis. Labeled bands were identified and semiquantitated by phosphorimaging. RT-PCR analysis demonstrated that ob/ob mice express lower amounts ofβ 3-AR RNA in their white (Fig. 3A) and brown (Fig. 3B) adipose tissues, compared with lean C57BL/6J mice, in agreement with others (14). Figure 3A shows the effect of saline, AOD9604, and hGH on β3-AR RNA expression in epididymal adipose tissue from both lean and obese mice, respectively. The level of β3-AR expression increased significantly in response to AOD9604 and hGH only in the obese mice, correlating with the significant decrease in epididymal adipose tissue weights seen in these mice. The same correlation was observed in brown adipose tissue, where increased expression of β3-AR was accompanied by a decrease in brown adipose tissue mass in both lean and obese mice (Fig. 3B).

The evidence so far suggests that there may be some effect on cartilage and bone densities, and it is correlated with weight loss. I understand that there is no evidence to suggest that it stimulates the release of IGF-1, which is the mechanism via which growth hormone gets most of its purported performance enhancing effects (i.e. muscle bulk). Whilst this is a decent list of things to test if one is considering AOD9604 as simply a variant of growth hormone, it is by no means exhaustive of all the mechanisms via which a drug can enhance athletic performance. The evidence thus far suggests that AOD9604 could be performance enhancing, but there is nothing I would hang my hat on. That is why I maintain that Dank is more sorcerer than scientist.
For example, studies have shown that people deficient in IGF-1 have an increased chance of dying from a heart attack. This is because IGF-1 prevents the death of heart cells and offers protection to heart cells when the cells are stressed, such as during a heart attack or long amount of time without oxygen. IGF-1 has a similar protective effect on brain cells.

Molly Hunsinger is a communications professional and certified group exercise instructor and fitness trainer. Her medical, health and fitness industry background spans nearly three decades with experience working as an instructor trainer, staff trainer, facility manager, group exercise program manager, physician relations manager and marketing director. As a media professional, she has developed and launched award-winning allied marketing and advertising campaigns for luxury retailers, leading nonprofit organizations and foundations and written numerous articles and blogs for both digital and print publications. Molly holds a bachelor’s degree in mass communications from the University of South Florida with a concentration in journalism and digital media studies.
Figure 2. A, Concentrations of plasma mature BNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. B, Concentrations of plasma Nt‐proBNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. BNP indicates B‐type natriuretic peptide; Nt‐proBNP, N‐terminal pro‐BNP.
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.

A total of 18 patients (3.6%) reported at least one SAE. The distribution of SAEs was similar among all treatment groups (Table 2). The most common SAEs reported were in the injury, poisoning and procedural complications body system class (6 patients, 1.2%). The others were general disorders and administration site conditions (2 patients; 0.4%), infections and infestations (2 patients; 0.4%), musculo-skeletal and connective tissue disorders (2 patients; 0.4%), and vascular disorders (2 patients; 0.4%).

We identified 34 patients who met eligibility criteria based on the chart review. Two subjects were excluded because they were found to have diabetes requiring insulin therapy, 1 was excluded because of hypothyroidism, and 13 were excluded because they did not undergo gastric bypass surgery or did not wish to participate. A final study sample of 18 individuals (15 women) was enrolled into the protocol. We had 3 individuals who did not complete the 6‐month follow‐up visit; the sample that completed both visits consisted of 15 individuals (12 women). No subjects were excluded because of peri‐operative complications. Table 1 displays the characteristics of the study sample at baseline and 6 months after surgery. From baseline to 6 months after surgery, subjects had a mean decrease of 27% in body mass index (P<0.0001). There were significant reductions in mean arterial blood pressure (P=0.004) and heart rate (P<0.001) after surgery. Only 2 out of 18 subjects were on any class of anti‐hypertensive medications at the pre‐op visit before gastric bypass surgery. At the 6‐month visit, anti‐hypertensive medication was discontinued for one of these subjects, and continued at the same dose for the other subject. The mean±SD volume of saline infusion pre‐bypass was 2.6±0.4 L and post‐bypass was 2.3±0.3 L.


ASADA gave advice to the ACC, and perhaps Essendon, that AOD-9604 was not banned under the S2 category. Given the expectation that AOD-9604 would not be anabolic because it lacked the ''anabolic region'' of HGH, it is perhaps understandable that ASADA did not classify it under S2 in 2011 and 2012, although its close structural relationship to the banned HGH should have been sufficient to include it on the banned list.
Cancer can often be a process of uncontrolled cellular division. IGF-1 is not only pro-growth in a way that could increase this cellular division, but IGF-1 also inhibits apoptosis, or programmed cell death. Hence the theory among some in the medical community that tumors could increase synthesis of IGF-1 to keep themselves alive and to encourage the spread of cancer throughout the body. This doesn’t mean that IGF-1 directly causes cancer.
Experimental animals were anesthetized with an intramuscular injection of xylazine (Rompun®; Bayer Co., Seoul, Korea) at a dose of 1.9 mg/kg and ketamine (Ketar®; Yuhan Co., Seoul, Korea) at a dose of 46 mg/kg. The right knee joints of all rabbits were shaved and sterilized. Then, 2 mg of collagenase type II from Clostridium histolyticum (Sigma Co., St. Louis, MO, USA) was prepared for intra-articular injection. Collagenase was dissolved in a sterile phosphate buffered saline (pH 7.4) and filtered with a 0.22-μm membrane. The solution was slowly injected into the right knee joint using ultrasound guidance. The same injection was repeated 3 days after the first injection, as previously reported (Figure 1) [8].
Similar to GHRP 2, this peptide is a more potent releaser of growth hormone, also acting on the ghrelin receptors of the anterior pituitary. Also like GHRP 2, GHRP 6 leads to increased growth hormone production, increased lead body mass, and decreased adiposity. Due to the peptide’s ghrelin-like properties, administration can lead to increased appetite.
In a statement to Fairfax Media on Thursday, Calzada Ltd said: ''The US generally recognised as safe 'GRAS' status is being explored as another viable commercial path for the company to pursue to potentially derive early revenue. Whilst AOD-9604 was not successful in human trials aimed at obesity, the Company believes there is sufficient efficacy data to enable a potential food, drink or dietary supplement product to be successfully marketed in the US.''
Peptide Clinics is an Australian owned and operated company, based in Sydney, that specialises in providing premium peptides online, coupled with expert medical guidance in their safe and effective use. Under the supervision of our experienced hormone doctors, Peptide Clinics Australia services thousands of clients throughout Australia with great success.
×